BeOne's degrader BG-60366 appears to have been discontinued.
ApexOnco Front Page
Recent articles
The disclosure comes as another of Arcus's TIGIT trials flops.
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.
JNJ-95566692 enters phase 1, with Qilu neck and neck.
Majestec-9, in post-Darzalex multiple myeloma, is the latest success.
Three private biotechs enter clinical trials, one targeting KRAS.
But PFS data are lacking, and there are questions about first and second-line plans.
